Comparison of the efficacy and safety of once-daily oral trovafloxacin and 3-times-daily amoxicillin/clavulanic acid for the treatment of complicated skin and soft-tissue infections

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 288-290

  Daniel, R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; TROVAFLOXACIN;

ABDOMINAL PAIN; ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS FAECALIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VERTIGO; VOMITING;

ENTEROCOCCUS FAECALIS; MIRABILIS; PROTEUS MIRABILIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0032750078     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00096     Document Type: Conference Paper

References (2)

1. Briggs-Gooding B, Jones RN. In vitro antimicrobial activity of CP-99,219 a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37: 349-53
2. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new fluoroquinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385-94